Aortic dissection stent graft maker Ascyrus Medical announced that it sold nearly $5.2 million in an equity offering.
The Boca Raton, Fla.–based company has no equity left to be sold in the offering, having collected approximately $5.18 million from six different investors. The minimum investment accepted was $39,997.
Ascyrus Medical did not disclose the issuer size for the offering, which was a new notice that made its first sale on Jan. 15 and lasted just 15 days before it was completed.
The company develops the AMDS device, which is designed to treat acute Type A aortic dissections, in which the lining of the abdominal aorta becomes detached from the wall of the vessel. Ascyrus won CE Mark approval in the European Union for the device in February.
Ascyrus Medical said it conducted dissection trials in Canada and Germany that showed a “significant reduction in mortality and re-interventions along with effective malperfusion management.” There were no device-related adverse events, according to the company.
Its aortic dissection stent graft won FDA breakthrough device designation in August 2019.
